IE
IMUX icon

Israel Englander’s Immunic IMUX Stock Holding History

Israel Englander’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-33,050
Closed -$1.15M – 7254
2022
Q2 		$1.15M Buy
33,050
+15,550
+89% +$996K ﹤0.01% 4245
2022
Q1 		$1.98M Buy
+17,500
New +$2.03M ﹤0.01% 3893

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Israel Englander's IMUX Position: Q2 2026 in Review

Israel Englander increased its Immunic (IMUX) stake by 96% in Q2 2026, buying an estimated $4.47M and bringing the position to 740,347 shares worth $11.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2153.

Israel Englander first reported a position in IMUX in Q4 2016 and has held it in 35 quarters since. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • Israel Englander held 740,347 shares of Immunic worth $11.4M as of Q2 2026.
  • Israel Englander bought 362,355 Immunic shares in Q2 2026, an estimated $4.47M.
  • Immunic made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2153 holding.
  • Israel Englander first reported a position in Immunic in Q4 2016 and has held it in 35 quarters since.
  • 55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.